These results support the therapeutic potential of KA1-P1 for treating chronic inflammatory diseases associated with NLRP3 activation, including bacterial and viral pneumonia, ARDS, and age-related lung inflammation. This evidence concerns the gene GRIK4 and viral pneumonia.